Kane Biotech (TSE:KNE) has released an update.
Kane Biotech Inc. has reported a significant second quarter in 2024, marked by a $10.4M gain from the sale of STEM and a robust 23% increase in total revenue compared to the previous year. The company has not only settled all interest-bearing debt but also expanded its market reach with new distribution agreements and advancements like the MDSAP Quality Certification and FDA clearance enhancements for their revyve Antimicrobial Wound Gel product.
For further insights into TSE:KNE stock, check out TipRanks’ Stock Analysis page.
